Do Pharmaceutical Firms Invest More Heavily in Countries with Data Exclusivity?

me[Forthcoming paper, Summer 2013, Currents International Trade Law Journal]   Abstract:   Countries may choose various methods of data protection in order to comply with the TRIPS Agreement. Policymakers should consider the effects of data exclusivity on prices and investment relative to other types of data protection. The data presented here suggest there is no relationship between whether or not a country has data exclusivity, and the amount of investment in the country by the pharmaceutical industry. On the other hand, empirical evidence in previous papers has shown that data exclusivity does drive prices higher.

Full paper available on SSRN at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2259797

 

Author

  • Mike Palmedo

    Mike Palmedo is the admin for infojustice.org, and he manages interdisciplinary research on copyright exceptions at American University College of Law's Program on Information Justice and Intellectual Property. He has Masters degrees Economics and in International Affairs, and is an economics PhD candidate.

Share

Related posts